Ketamine for Treatment-Resistant Depression: The First Decade of Progress - Image 1

£80.67

Adis Ketamine for Treatment-Resistant Depression: The First Decade of Progress

Name: Ketamine for Treatment-Resistant Depression: The First Decade of Progress
Brand: Adis
Price: 80.67 GBP
Availability: InStock

Depression

This is the most expensive it has ever been. Walk away.

£81 today · previous high £81 · all-time low £73

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 67 days · 67 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 67 days • 2 price levels

Days at Price

Current Price

Price Analysis

Most common price: £81 (64 days, 95.5%)

Price range: £73 - £81

Price levels: 2 different prices over 67 days

Description

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic moleculartargets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Product Specifications

Brand: Adis
Format: hardcover
ASIN: 331942923X
Category: Books > Subjects > Health, Family & Lifestyle > Health Issues > Illnesses & Conditions > Depression
Domain: Amazon UK
Release Date: 15 December 2016
Listed Since: 15 June 2016

Barcode

No barcode data available

Adis Ketamine for Treatment-Resistant Depression: The First Decade of Progress

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Ketamine for Treatment-Resistant Depression: The First Decade of Progress

Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects (Experimental and Clinical Neuroscience)

Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects (Experimental and Clinical Neuroscience)

Brain Function and Psychotropic Drugs (Oxford Medical Publications)

Neurobiology of Depression: Road to Novel Therapeutics

Pediatric Psychopharmacology: Principles and Practice

In Vivo Neuropharmacology and Neurophysiology: 121 (Neuromethods, 121)

Major Depressive Disorder: Risk Factors, Characteristics & Treatment Options (Psychiatry - Theory, Applications and Treatments)

In Vivo Neuropharmacology and Neurophysiology: 121 (Neuromethods, 121)

Psychopharmacology: 13 (Neuromethods, 13)

Molecular Psychiatry

5-HT2C Receptors in the Pathophysiology of CNS Disease: 22 (The Receptors, 22)

Neuroscience for Psychologists and Other Mental Health Professionals: Promoting Well-Being and Treating Mental Illness

Drug Development in Psychiatry: 30 (Advances in Neurobiology, 30)

Electrophysiology and Psychophysiology in Psychiatry and Psychopharmacology: 21 (Current Topics in Behavioral Neurosciences, 21)

A PRACTICAL GUIDE TO TRANSCRANIAL MAGNETIC STIMULATION NEUROPHYSIOLOGY

Interventional Psychiatry: Road to Novel Therapeutics

Massachusetts General Hospital Psychopharmacology and Neurotherapeutics

New Rapid-acting Antidepressants (Contemporary Clinical Neuroscience)

Kaplan and Sadock’s Pocket Handbook of Psychiatric Drug Treatment

Facilitating Resilience after PTSD: A Translational Approach (Psychiatry - Theory, Applications and Treatments)

Greenshaw: Experimental ∗psychopharmacology∗ – Concepts & Methods (Contemporary Neuroscience)

The Nature of Depression: An Updated Review

Springer Clinical Pharmacology in Psychiatry - Vol 10